• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Latest News

FDA Approves Exact Sciences' Cologuard Plus Non-Invasive Colorectal Cancer Screening Test
FDA Approves Exact Sciences' Cologuard Plus Non-Invasive Colorectal Cancer Screening Test

October 4th 2024

Approval of Cologuard Plus follows results from the BLUE-C study, which demonstrated a 95% sensitivity for detecting colorectal cancer.

FDA Approves Bristol Myers Squibb’s Opdivo in Combination with Chemotherapy for Resectable Non-Small Cell Lung Cancer
FDA Approves Bristol Myers Squibb’s Opdivo in Combination with Chemotherapy for Resectable Non-Small Cell Lung Cancer

October 4th 2024

Animating for Your Audience: The Right Visual for Your Dev Stage
Animating for Your Audience: The Right Visual for Your Dev Stage

October 4th 2024

Stock.adobe.com
BCS Financial Introduces Employer Group Gene Therapy Stop Loss

October 4th 2024

Claire Wagner
Combating Diseases with Limited Investment Incentives: Q&A with Dr. Claire Wagner

October 4th 2024

Pharmaceutical Executive: September 2024 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.

 Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.

Conference Coverage

View All
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

June 4th 2024

Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection
Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection

June 4th 2024

Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer
Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer

June 3rd 2024

Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status
Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status

June 3rd 2024

Latest Videos
Podcasts

All News